Have you ever wondered how pharmaceutical companies are encouraged to develop therapies for rare diseases? And whether or not this system is working?
We will cover these topics and more in an educational webinar on June 12. Join us as NORD’s Director of Federal Policy Paul Melmeyer discusses the importance of the Orphan Drug Act, gives an overview of how a drug is developed, and dispels some of the common myths about the process.
This webinar will be perfect for patients, caregivers, advocates, and researchers who want to learn more about drug development and the Orphan Drug Act.